Billiontoone (NASDAQ:BLLN) Insider Sells $2,563,575.00 in Stock

Billiontoone, Inc. (NASDAQ:BLLN) insider Oguzhan Atay sold 26,250 shares of the stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $97.66, for a total value of $2,563,575.00. Following the completion of the sale, the insider directly owned 20,000 shares of the company’s stock, valued at $1,953,200. This represents a 56.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oguzhan Atay also recently made the following trade(s):

• On Monday, June 8th, Oguzhan Atay sold 12,500 shares of Billiontoone stock. The shares were sold at an average price of $98.22, for a total value of $1,227,750.00.

Billiontoone Price Performance

Shares of BLLN traded down $3.13 during mid-day trading on Wednesday, hitting $99.26. The company’s stock had a trading volume of 1,040,614 shares, compared to its average volume of 694,048. Billiontoone, Inc. has a one year low of $61.96 and a one year high of $138.70. The company has a quick ratio of 10.58, a current ratio of 10.92 and a debt-to-equity ratio of 0.18. The stock’s 50-day moving average is $87.26 and its two-hundred day moving average is $88.18.

Billiontoone (NASDAQ:BLLN) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.33. The business had revenue of $108.39 million during the quarter, compared to the consensus estimate of $95.81 million. During the same period in the prior year, the company posted ($0.39) earnings per share. The firm’s revenue was up 83.8% compared to the same quarter last year. Sell-side analysts forecast that Billiontoone, Inc. will post 0.93 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Rossby Financial LCC acquired a new position in Billiontoone during the fourth quarter worth $25,000. Wells Fargo & Company MN acquired a new position in Billiontoone during the fourth quarter worth $76,000. Smartleaf Asset Management LLC acquired a new position in Billiontoone during the fourth quarter worth $80,000. Nano Cap New Millennium Growth Fund L P acquired a new position in Billiontoone during the fourth quarter worth $82,000. Finally, Renaissance Capital LLC acquired a new position in Billiontoone during the fourth quarter worth $201,000.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on BLLN. BTIG Research reduced their price objective on Billiontoone from $140.00 to $130.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Weiss Ratings lowered Billiontoone from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, June 5th. Wells Fargo & Company cut their target price on Billiontoone from $110.00 to $90.00 and set an “equal weight” rating for the company in a research note on Thursday, March 5th. Guggenheim upped their target price on Billiontoone from $100.00 to $120.00 and gave the company a “buy” rating in a research note on Wednesday, May 13th. Finally, Wall Street Zen upgraded Billiontoone from a “hold” rating to a “buy” rating in a research note on Saturday, March 7th. Six equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $125.29.

Billiontoone Company Profile

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.